Study Identifies Biomarkers for Metformin Response in Patients With Diabetes

September 21, 2020

The study marks the first pharmacoepigenetic study in diabetes evaluating epigenetic factors as biomarkers to predict a drug’s effects on an individual.

FDA Fast Tracks Empagliflozin to Improve Outcomes Following Heart Attack

September 18, 2020

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

FDA Approves New Doses of Dulaglutide for the Treatment of Type 2 Diabetes

September 08, 2020

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

FDA OKs Hybrid Closed Loop Diabetes Management Device for Use in Young Children

September 01, 2020

The MiniMed 770G system (Medtronic) is approved for use by individuals aged 2 to 6 with type 1 diabetes.

Dapagliflozin Reduces Risk of Kidney Failure, Death in Chronic Kidney Disease

August 31, 2020

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

FDA Removes Boxed Warning for Amputation Risk From Canagliflozin

August 27, 2020

The removal of the boxed warning from canagliflozin was based on the FDA’s review of new data from 3 clinical trials.

Metabolic Syndrome Linked to Increased Risk of COVID-19 Mortality

August 26, 2020

Individuals with metabolic syndrome who were hospitalized for COVID-19 were more likely to experience worse outcomes.

Bayshore Recalls 2 Lots of Extended-Release Metformin

August 21, 2020

Bayshore Pharmaceuticals issued a voluntary recall of 2 lots of its extended-release metformin products due to high levels of NDMA.

Lilly Expands Insulin Affordability Solutions

August 11, 2020

Lilly is committed to helping people who face high out-of-pocket costs for insulin by offering a broad suite of affordable solutions.

Youth Involvement in Decision to Start CGM Linked to Consistent Use

August 04, 2020

Youth with diabetes who are involved in the decision to start continuous glucose monitoring reported consistent use 2 months after starting.

COVID-19 Effects on Patients with Diabetes

July 31, 2020

Joshua Miller, MD MPH and medical director of diabetes care for Stony Brook Medicine, discusses continuous glucose monitoring (CGM) technology, which the FDA has authorized for use in hospitals amid the COVID-19 pandemic.

Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial

July 31, 2020

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Americans with Diabetes Struggle with Medical Costs During Pandemic

July 30, 2020

Unemployment rates compounded with high medical costs plague the diabetes community during the coronavirus disease 2019 (COVID-19) pandemic.

Go to Bat for Patients in Need

July 27, 2020

“I just hope that pharmacists’ judgment can soon be a contributing factor in pharmacotherapy decisions made by PBMs and insurance companies.”

Episode 6: High Risk: Diabetes and COVID-19

July 24, 2020

In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.

Study Determines Association Between Mortality Rates and Sleep Duration in Adults with Type 2 Diabetes

July 23, 2020

Individuals with type 2 diabetes who exhibit extreme sleep duration hours may have a higher risk of death than individuals without diabetes.

Gut Bacteria Contribute to Improved Prediction of Type 2 Diabetes

July 08, 2020

Type 2 diabetes risk prediction is improved by observing changes in gut bacteria, a study finds.

Ready-to-Use Glucagon Injection for Severe Hypoglycemia Now Available

July 06, 2020

Xeris Pharmaceuticals’ new glucagon injection (Gvoke HypoPen), a ready-to-use glucagon formulation in a premixed autoinjector, is now available by prescription.

Risk of Death By Heart Failure Increases With Recent Diagnosis of Type 2 Diabetes

July 02, 2020

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

CDC: Partnerships With Pharmacists Expand Diabetes Prevention Efforts

July 01, 2020

The CDC has identified the pharmacy sector as a key partner in offering its lifestyle change-based program for patients with high risk for type 2 diabetes.